Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-01-01 DOI:10.21873/invivo.13833

Risa Nishiyama, Toshiya Kagoo, Hironori Ueno, Akihiro Yokoyama

{"title":"Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up.","authors":"Risa Nishiyama, Toshiya Kagoo, Hironori Ueno, Akihiro Yokoyama","doi":"10.21873/invivo.13833","DOIUrl":null,"url":null,"abstract":"Background/aim: Autologous stem cell transplantation (ASCT) is the standard strategy after induction therapy for newly diagnosed transplant-eligible multiple myeloma. High-dose melphalan (HDM) conditioning has been the recommended treatment regimen for a long time. No other conditioning regimen has been proven safer and more effective. Because bortezomib has a synergistic effect with melphalan, bortezomib with HDM (Bor-HDM) as a conditioning regimen has shown favorable outcomes, improved complete response rates after ASCT, and no prolonged hematological toxicities. However, few studies have reported long-term follow-up data. This study aimed to evaluate the long-term progression-free survival (PFS) and overall survival (OS) of patients receiving Bor-HDM conditioning, compared to those treated with HDM alone.Patients and methods: This single-center retrospective study included 36 patients newly diagnosed with transplant-eligible myeloma from 2008 to 2020. In total, 15 patients received a Bor-HDM regimen, while 21 patients received HDM as a conditioning regimen. The probabilities of PFS and OS were plotted using the Kaplan-Meier method. All statistical analyses were performed using EZR software.Results: After a median follow up of 77 months, no severe hematological toxicities were observed. The PFS and OS rates in the Bor-HDM group as compared with the HDM group were 0.762 vs. 0.60 (p=0.409) and 0.80 vs. 0.904 (p=0.476) respectively. No significant differences were observed between the two groups.Conclusion: These long-term results show that Bor-HDM is a safe and effective option for ASCT conditioning regimens.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"340-345"},"PeriodicalIF":1.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705111/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13833","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Autologous stem cell transplantation (ASCT) is the standard strategy after induction therapy for newly diagnosed transplant-eligible multiple myeloma. High-dose melphalan (HDM) conditioning has been the recommended treatment regimen for a long time. No other conditioning regimen has been proven safer and more effective. Because bortezomib has a synergistic effect with melphalan, bortezomib with HDM (Bor-HDM) as a conditioning regimen has shown favorable outcomes, improved complete response rates after ASCT, and no prolonged hematological toxicities. However, few studies have reported long-term follow-up data. This study aimed to evaluate the long-term progression-free survival (PFS) and overall survival (OS) of patients receiving Bor-HDM conditioning, compared to those treated with HDM alone.

Patients and methods: This single-center retrospective study included 36 patients newly diagnosed with transplant-eligible myeloma from 2008 to 2020. In total, 15 patients received a Bor-HDM regimen, while 21 patients received HDM as a conditioning regimen. The probabilities of PFS and OS were plotted using the Kaplan-Meier method. All statistical analyses were performed using EZR software.

Results: After a median follow up of 77 months, no severe hematological toxicities were observed. The PFS and OS rates in the Bor-HDM group as compared with the HDM group were 0.762 vs. 0.60 (p=0.409) and 0.80 vs. 0.904 (p=0.476) respectively. No significant differences were observed between the two groups.

Conclusion: These long-term results show that Bor-HDM is a safe and effective option for ASCT conditioning regimens.

查看原文本刊更多论文

硼替佐米联合大剂量美法兰调理方案治疗新诊断多发性骨髓瘤患者：长期随访

背景/目的：自体干细胞移植（ASCT）是新诊断的适合移植的多发性骨髓瘤诱导治疗后的标准策略。长期以来，高剂量美法兰（HDM）调节一直是推荐的治疗方案。没有其他调理方案被证明更安全、更有效。由于硼替佐米与美法兰具有协同作用，硼替佐米与HDM （Bor-HDM）作为一种调节方案显示出良好的结果，提高了ASCT后的完全缓解率，并且没有延长的血液毒性。然而，很少有研究报告长期随访数据。本研究旨在评估接受Bor-HDM治疗的患者与单独接受HDM治疗的患者的长期无进展生存期（PFS）和总生存期（OS）。患者和方法：这项单中心回顾性研究纳入了2008年至2020年36例新诊断为适合移植的骨髓瘤患者。总共有15名患者接受了Bor-HDM方案，而21名患者接受了HDM作为调节方案。采用Kaplan-Meier方法绘制PFS和OS的概率。所有统计分析均采用EZR软件进行。结果：中位随访77个月后，未观察到严重的血液毒性。与HDM组相比，Bor-HDM组的PFS和OS率分别为0.762比0.60 （p=0.409）和0.80比0.904 （p=0.476）。两组间无显著差异。结论：这些长期结果表明Bor-HDM是ASCT治疗方案中安全有效的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.